Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elevance Health, Inc.ANTM · Entity 2934 | EVP & CEO, IngenioRx | May 03, 2018 | May 07, 2018 |
| Healthcare Services Acquisition CorpHCARU · Entity 144453 | Director | December 22, 2020 | December 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elevance Health, Inc.
Report date May 03, 2018 · Filed May 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,863 |
Ending reported balance
After 2018-05-03 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2018-05-03 · Exercise / conversion · Acquired 9,756 · Balance 25,619 Row 2 · 2018-05-03 · Exercise / conversion · Acquired 7,489 · Balance 33,108 Row 3 · 2018-05-03 · Exercise / conversion · Acquired 14,830 · Balance 47,938 Row 4 · 2018-05-03 · Exercise / conversion · Acquired 4,478 · Balance 52,416 Row 5 · 2018-05-03 · Exercise / conversion · Acquired 16,232 · Balance 68,648 Row 6 · 2018-05-03 · Exercise / conversion · Acquired 6,636 · Balance 75,284 Row 7 · 2018-05-03 · Sale · Disposed 54,497 · Balance 20,787 F1: This transaction was executed in multiple trades at prices ranging from $224.13 to $225.10. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2018-05-03 · Sale · Disposed 4,924 · Balance 15,863 F2: This transaction was executed in multiple trades at prices ranging from $225.15 to $225.49. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.88 · Expires 2020-03-01 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-05-03 · Exercise / conversion · Disposed 9,756 · Balance 0 F3: The option represents a right to purchase a total of 9,756 shares, and is exercisable in six semi-annual installments of 1,626 shares each, beginning on September 1, 2013, which is the six-month anniversary of the option grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.93 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-05-03 · Exercise / conversion · Disposed 7,489 · Balance 0 F4: The option represents a right to purchase a total of 7,489 shares, and is exercisable in five semi-annual installments of 1,248 shares each and one installment of 1,249 shares, beginning on September 2, 2015, which is the six-month anniversary of the option grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.44 · Expires 2021-03-03 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-05-03 · Exercise / conversion · Disposed 14,830 · Balance 0 F5: The option represents a right to purchase a total of 14,830 shares, and is exercisable in six semi-annual installments, with two installments of 2,471 shares each and four installments of 2,472 shares each, beginning on September 3, 2014, which is the six-month anniversary of the option grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $152.78 · Expires 2025-08-03 | Direct | 896 |
Reported balance
After 2018-05-03 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-05-03 · Exercise / conversion · Disposed 4,478 · Balance 896 F6: The option represents a right to purchase a total of 5,374 shares, and is exercisable in six semi-annual installments, with two installments of 895 shares each and four installments of 896 shares each, beginning on February 3, 2016, which is the six-month anniversary of the option grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.80 · Expires 2026-03-01 | Direct | 8,116 |
Reported balance
After 2018-05-03 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-05-03 · Exercise / conversion · Disposed 16,232 · Balance 8,116 F7: The option represents a right to purchase a total of 24,348 shares, and is exercisable in six semi-annual installments of 4,058 shares each, beginning on September 1, 2016, which is the six-month anniversary of the option grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $166.97 · Expires 2027-03-01 | Direct | 13,272 |
Reported balance
After 2018-05-03 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-05-03 · Exercise / conversion · Disposed 6,636 · Balance 13,272 F8: The option represents a right to purchase a total of 19,908 shares, and is exercisable in six semi-annual installments of 3,318 shares each, beginning on September 1, 2017, which is the six-month anniversary of the option grant date. |
| Common StockSEC Table I · non-derivative | Indirect2016 GRAT Trust | 2,245 |
Reported balance
Holding disclosure · report date 2018-05-03 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 2,245 |
| Common StockSEC Table I · non-derivative | Indirect2017 GRAT I Trust | 17,767 |
Reported balance
Holding disclosure · report date 2018-05-03 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 17,767 |
| Common StockSEC Table I · non-derivative | Indirect2017 GRAT II Trust | 17,767 |
Reported balance
Holding disclosure · report date 2018-05-03 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 17,767 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $224.13 to $225.10. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $225.15 to $225.49. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The option represents a right to purchase a total of 9,756 shares, and is exercisable in six semi-annual installments of 1,626 shares each, beginning on September 1, 2013, which is the six-month anniversary of the option grant date.
F4: The option represents a right to purchase a total of 7,489 shares, and is exercisable in five semi-annual installments of 1,248 shares each and one installment of 1,249 shares, beginning on September 2, 2015, which is the six-month anniversary of the option grant date.
F5: The option represents a right to purchase a total of 14,830 shares, and is exercisable in six semi-annual installments, with two installments of 2,471 shares each and four installments of 2,472 shares each, beginning on September 3, 2014, which is the six-month anniversary of the option grant date.
F6: The option represents a right to purchase a total of 5,374 shares, and is exercisable in six semi-annual installments, with two installments of 895 shares each and four installments of 896 shares each, beginning on February 3, 2016, which is the six-month anniversary of the option grant date.
F7: The option represents a right to purchase a total of 24,348 shares, and is exercisable in six semi-annual installments of 4,058 shares each, beginning on September 1, 2016, which is the six-month anniversary of the option grant date.
F8: The option represents a right to purchase a total of 19,908 shares, and is exercisable in six semi-annual installments of 3,318 shares each, beginning on September 1, 2017, which is the six-month anniversary of the option grant date.
Healthcare Services Acquisition Corp
Report date December 22, 2020 · Filed December 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Shares of Class B Common Stock will automatically convert into shares of the Issuer's Class A Common Stock at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, or earlier at the option of the holder thereof, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-249389) and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class B Common Stock will automatically convert into shares of the Issuer's Class A Common Stock at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, or earlier at the option of the holder thereof, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-249389) and have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CRH Medical Corp
Report date April 22, 2021 · Filed April 27, 2021
Section 16 reporting ended · disclosed 2021-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2024-05-26 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. F2: Each CRH RSU represented a contingent right to receive one CRH share. F3: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2021-06-11 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-22 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. F2: Each CRH RSU represented a contingent right to receive one CRH share. F3: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held.
F2: Each CRH RSU represented a contingent right to receive one CRH share.
F3: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs.
Diplomat Pharmacy, Inc.
Report date February 10, 2020 · Filed February 10, 2020
Section 16 reporting ended · disclosed 2020-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-10 transaction · row 1
1 source rowRow 1 · 2020-02-10 · Other · Disposed 11,238 · Balance 0 F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. |
| Common StockSEC Table I · non-derivative | IndirectBy grantor retained annuity trust | 0 |
Last balance in matching sequence
After 2020-02-10 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 2 · 2020-02-10 · Other · Disposed 124,875 · Balance 1,303,805 F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Row 3 · 2020-02-10 · Disposition to issuer · Disposed 22,478 · Balance 1,281,327 F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Row 4 · 2020-02-10 · Disposition to issuer · Disposed 84,375 · Balance 1,196,952 F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Row 5 · 2020-02-10 · Disposition to issuer · Disposed 408,915 · Balance 788,037 F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Row 6 · 2020-02-10 · Disposition to issuer · Disposed 583,580 · Balance 204,457 F4: Pursuant to the Merger Agreement, certain vested restricted stock unit awards held by reporting person were disposed of pursuant to the closing on February 10, 2020 of the Tender Offer. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Row 7 · 2020-02-10 · Disposition to issuer · Disposed 204,457 · Balance 0 F4: Pursuant to the Merger Agreement, certain vested restricted stock unit awards held by reporting person were disposed of pursuant to the closing on February 10, 2020 of the Tender Offer. F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. |
| Employee Stock Option to Acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,705.75 · Expires 2028-06-04 | IndirectBy grantor retained annuity trust | 0 |
Reported balance
After 2020-02-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-10 · Disposition to issuer · Disposed 81,351 · Balance 0 F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F5: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2018). F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. |
| Employee Stock Option to Acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $337.78 · Expires 2029-06-04 | IndirectBy grantor retained annuity trust | 0 |
Reported balance
After 2020-02-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-10 · Disposition to issuer · Disposed 290,198 · Balance 0 F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F6: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2019). F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest.
F2: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II.
F3: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements.
F4: Pursuant to the Merger Agreement, certain vested restricted stock unit awards held by reporting person were disposed of pursuant to the closing on February 10, 2020 of the Tender Offer.
F5: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2018).
F6: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2019).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2021 Filed Apr 27, 2021 20:02 UTC | CRH Medical Corp CRHM · Entity 139998 | Disposition to issuerRestricted Share Units · Derivative | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001209191-21-028730 · doc4.xml · derivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2021-06-11 F1 · security: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. F2 · derivative.exercise_price: Each CRH RSU represented a contingent right to receive one CRH share. F3 · derivative.exercise_date: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 20:02 UTC | CRH Medical Corp CRHM · Entity 139998 | Disposition to issuerRestricted Share Units · Derivative | 50,000 | $4.00 | $200,000.00 |
DisclosureSEC source: 0001209191-21-028730 · doc4.xml · derivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2024-05-26 F1 · security: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. F2 · derivative.exercise_price: Each CRH RSU represented a contingent right to receive one CRH share. F3 · derivative.exercise_date: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:09 UTC | CRH Medical Corp CRHM · Entity 139998 | GrantRestricted Share Unit · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036820 · doc4.xml · derivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F2 · derivative.exercise_date: Restricted Share Units vest on or before expiration date. F3 · derivative.expiration_date: The Restricted Share Units will expire on the earlier of June 30, 2021 or one day prior to the next Annual General Meeting of the Issuer. Read SEC document |
| May 26, 2020 Filed May 28, 2020 16:15 UTC | CRH Medical Corp CRHM · Entity 139998 | GrantRestricted Share Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032582 · doc4.xml · derivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2024-05-26 F1 · derivative.exercise_price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F2 · derivative.exercise_date: Restricted Share Units vest 25% on the first year anniversary, 25% on the second year anniversary, 25% on the third year anniversary and the final 25% on the expiration date. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerEmployee Stock Option to Acquire Common Stock · Derivative | 290,198 | $0.00 Strike: $337.78 | $0.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · derivative · entry 9 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 Underlying: Common Stock · 290,198 shares Expires 2029-06-04 F3 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F3 · price: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F6 · derivative.exercise_date: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2019). F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerEmployee Stock Option to Acquire Common Stock · Derivative | 81,351 | $0.00 Strike: $1,705.75 | $0.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · derivative · entry 8 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 Underlying: Common Stock · 81,351 shares Expires 2028-06-04 F3 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F3 · price: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F5 · derivative.exercise_date: One-third of the options vest on each of the first, second and third anniversary of the grant date (June 4, 2018). F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 204,457 | $4.00 | $817,828.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 7 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 F4 · kind: Pursuant to the Merger Agreement, certain vested restricted stock unit awards held by reporting person were disposed of pursuant to the closing on February 10, 2020 of the Tender Offer. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 583,580 | $4.00 | $2,334,320.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 6 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 204,457 F4 · kind: Pursuant to the Merger Agreement, certain vested restricted stock unit awards held by reporting person were disposed of pursuant to the closing on February 10, 2020 of the Tender Offer. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 408,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 5 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 788,037 F3 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 84,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 4 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 1,196,952 F3 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 22,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 3 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 1,281,327 F3 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), certain outstanding restricted stock unit awards held by reporting person were converted into equity awards of the Parent pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. These shares remain subject to time-based vesting requirements. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | OtherCommon Stock | 124,875 | $4.00 | $499,500.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 1,303,805 F1 · kind: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:16 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | OtherCommon Stock | 11,238 | $4.00 | $44,952.00 |
DisclosureSEC source: 0001104659-20-013506 · a4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:05 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 613,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-20-000001 · primary_doc.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 1,428,680 F3 · shares: On June 4, 2019, reporting person was granted restricted stock units that were subject to the Issuer's satisfaction of certain financial performance criteria. On February 4, 2020 (the "determination date"), the performance criteria was met with respect to 613,372 restricted stock units. One-third of the restricted stock units vested upon the determination date, and the remaining two-thirds will vest in two equal installments on each anniversary of the determination date, subject to continued employment. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:05 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 583,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-20-000001 · primary_doc.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · BY grantor retained annuity trust Disclosed balance after: 815,308 F1 · shares: On June 4, 2018, reporting person was granted restricted stock units that were subject to the Issuer's satisfaction of certain financial performance criteria. On February 4, 2020 (the "determination date"), the performance criteria was met with respect to 583,580 restricted stock units all of which vested upon the determination date. F2 · ownership.nature: These shares are held by the Brian T. Griffin 2019 Grantor Retained Annuity Trust No. II. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:03 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantEmployee Stock Option to Acquire Common Stock · Derivative | 290,198 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001596771-19-000059 · primary_doc.xml · derivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,198 Underlying: Common Stock · 290,198 shares Expires 2029-06-04 F2 · derivative.exercise_date: The options were granted in connection with the Issuer's equity incentive plan. One-third of the options will vest on each of the first, second and third anniversary of the grant date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:03 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 84,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-19-000059 · primary_doc.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,966 F1 · shares: Restricted stock units ("RSUs") granted in connection with the Issuer's equity incentive plan. One-third of the RSUs will vest on each of the first, second and third anniversary of the grant date. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:38 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantEmployee Stock Option to Acquire Common Stock · Derivative | 81,351 | $0.00 Strike: $24.29 | $0.00 |
DisclosureSEC source: 0001596771-18-000076 · primary_doc.xml · derivative · entry 3 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,351 Underlying: Common Stock · 81,351 shares Expires 2028-06-04 F4 · derivative.exercise_date: Represents an inducement award of stock options to the reporting person in connection with his appointment as CEO and Chairman. One-third of the options will vest on each of the first, second and third anniversary of the grant date. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:38 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 124,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000076 · primary_doc.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,591 F1 · shares: The restricted stock units ("RSUs") represent an inducement award of stock to the reporting person in connection with his appointment as CEO and Chairman. F3 · shares: The RSUs will vest on the first anniversary of the grant date, provided the vesting of these RSUs may be accelerated based on the achievement of a specified stock price performance goal. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:38 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 33,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000076 · primary_doc.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,716 F1 · shares: The restricted stock units ("RSUs") represent an inducement award of stock to the reporting person in connection with his appointment as CEO and Chairman. F2 · shares: One-third of the RSUs will vest on each of the first, second and third anniversary of the grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,636 | $0.00 Strike: $166.97 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 17 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,272 Underlying: Common Stock · 6,636 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option represents a right to purchase a total of 19,908 shares, and is exercisable in six semi-annual installments of 3,318 shares each, beginning on September 1, 2017, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,232 | $0.00 Strike: $131.80 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 16 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,116 Underlying: Common Stock · 16,232 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option represents a right to purchase a total of 24,348 shares, and is exercisable in six semi-annual installments of 4,058 shares each, beginning on September 1, 2016, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,478 | $0.00 Strike: $152.78 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 15 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896 Underlying: Common Stock · 4,478 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option represents a right to purchase a total of 5,374 shares, and is exercisable in six semi-annual installments, with two installments of 895 shares each and four installments of 896 shares each, beginning on February 3, 2016, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,830 | $0.00 Strike: $89.44 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 14 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,830 shares Expires 2021-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option represents a right to purchase a total of 14,830 shares, and is exercisable in six semi-annual installments, with two installments of 2,471 shares each and four installments of 2,472 shares each, beginning on September 3, 2014, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,489 | $0.00 Strike: $146.93 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 13 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,489 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option represents a right to purchase a total of 7,489 shares, and is exercisable in five semi-annual installments of 1,248 shares each and one installment of 1,249 shares, beginning on September 2, 2015, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,756 | $0.00 Strike: $61.88 | $0.00 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · derivative · entry 12 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,756 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option represents a right to purchase a total of 9,756 shares, and is exercisable in six semi-annual installments of 1,626 shares each, beginning on September 1, 2013, which is the six-month anniversary of the option grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | SaleCommon Stock | 4,924 | $225.35 | $1,109,623.40 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 8 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,863 F2 · price: This transaction was executed in multiple trades at prices ranging from $225.15 to $225.49. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | SaleCommon Stock | 54,497 | $224.32 | $12,224,767.04 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 7 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,787 F1 · price: This transaction was executed in multiple trades at prices ranging from $224.13 to $225.10. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 6,636 | $166.97 | $1,108,012.92 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 6 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 16,232 | $131.80 | $2,139,377.60 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 5 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 4,478 | $152.78 | $684,148.84 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 4 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 14,830 | $89.44 | $1,326,395.20 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 3 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 7,489 | $146.93 | $1,100,358.77 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Exercise / conversionCommon Stock | 9,756 | $61.88 | $603,701.28 |
DisclosureSEC source: 0001127602-18-016509 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & CEO, IngenioRx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:44 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 5,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010098 · form4.xml · nonDerivative · entry 4 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,863 F3 · shares: Represents performance based restricted share units. Restrictions lapsed on 3/2/18. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:44 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 2,259 | $233.08 | $526,527.72 |
DisclosureSEC source: 0001127602-18-010098 · form4.xml · nonDerivative · entry 3 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,401 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:44 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,761 | $0.00 Strike: $232.04 | $0.00 |
DisclosureSEC source: 0001127602-18-010098 · form4.xml · derivative · entry 8 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,761 Underlying: Common Stock · 14,761 shares Expires 2028-03-01 F5 · derivative.exercise_date: The option represents a right to purchase a total of 14,761 shares, and is exercisable in six semi-annual installments, with five installments of 2,460 shares each and one installment of 2,461 shares, beginning on September 1, 2018, which is the six-month anniversary of the option grant date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:44 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 3,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010098 · form4.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,660 F2 · shares: Represents restricted share units. Restrictions lapse as follows: 1,167 shares each on 3/1/2019 and 3/1/2020, and 1,168 on 3/1/2021. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:44 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 856 | $232.04 | $198,626.24 |
DisclosureSEC source: 0001127602-18-010098 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:34 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 213 | $191.44 | $40,776.72 |
DisclosureSEC source: 0001127602-17-025138 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,078 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:02 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 2,356 | $166.49 | $392,250.44 |
DisclosureSEC source: 0001127602-17-014313 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,291 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 21:19 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 1,963 | $166.00 | $325,858.00 |
DisclosureSEC source: 0001127602-17-010583 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,647 F1 · price: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 21:41 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 213 | $165.97 | $35,351.61 |
DisclosureSEC source: 0001127602-17-010201 · form4.xml · nonDerivative · entry 3 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,610 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:41 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 19,908 | $0.00 Strike: $166.97 | $0.00 |
DisclosureSEC source: 0001127602-17-010201 · form4.xml · derivative · entry 6 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,908 Underlying: Common Stock · 19,908 shares Expires 2027-03-01 F4 · derivative.exercise_date: The option represents a right to purchase a total of 19,908 shares, and is exercisable in six semi-annual installments of 3,318 shares each, beginning on September 1, 2017, which is the six-month anniversary of the option grant date. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:41 UTC | Elevance Health, Inc. ANTM · Entity 2934 | GrantCommon Stock | 4,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010201 · form4.xml · nonDerivative · entry 2 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,823 F2 · shares: Represents restricted share units. Restrictions lapse as follows: 1,622 shares each on 3/1/2018 and 3/1/2019, and 1,623 on 3/1/2020. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:41 UTC | Elevance Health, Inc. ANTM · Entity 2934 | Tax withholdingCommon Stock | 706 | $166.97 | $117,880.82 |
DisclosureSEC source: 0001127602-17-010201 · form4.xml · nonDerivative · entry 1 GRIFFIN BRIAN T · CIK 0001252006 · EVP & President, CSBD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,956 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.